CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,189 enrolled
Drug / intervention
DTaP-IPV-HB-PRP~T vaccine +3 morebiological
Likely dose
DTaP-IPV-HB-PRP~T vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00404651
NCT00404651Phase 3Completed

Lot to Lot Consistency Study of DTaP-IPV-Hep B-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Mexican Infants

Sanofi Pasteur, a Sanofi Company·interventional·Posted Nov 29, 2006·Updated May 9, 2014

In Brief

A Phase 3 clinical trial evaluating DTaP-IPV-HB-PRP~T vaccine and DTaP-HBV-IPV vaccine for Diphtheria and 4 related conditions. Completed, enrolled 1,189 participants across 6 sites.

Detailed Summary

The purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational DTaP-IPV-HB-PRP\~T vaccine is consistent. The primary objective is to demonstrate the equivalence of three batches of DTaP-IPV-HB-PRP\~T vaccine, in terms of seroprotection and seroconversion rates for the vaccine antigens after the three-dose primary series. The secondary objectives are: * To describe in each group, the immunogenicity parameters for all antigens one month after the third dose of the primary series * To assess the overall safety in each group one month after the third dose of the primary series.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMexico
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 29, 2006
Enrollment StartNov 1, 2006
Primary CompletionApr 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.6 years ago

Interventions

DTaP-IPV-HB-PRP~T vaccinebiological

0.5 mL, intramuscular (IM)

DTaP-IPV-HB-PRP~T vaccinebiological

0.5 mL, IM

DTaP-IPV-HB-PRP~T vaccinebiological

0.5 mL, IM

DTaP-HBV-IPV vaccinebiological

0.5 mL, IM